Fundz

Nkarta, Inc. reported raising $43.9 Million in an initial SEC Form D filing, from an offering of $115 Million

PUBLIC · NKTXSep 06, 2019$43.9M of $114.6M raised

Amount Raised

$43.9 Million

$43.9 Million sold, per SEC Form D (first sale Sep 6, 2019)

Round Type

Venture

South San FranciscoBiotechnology

Quick answer

Nkarta raised $43.9 Million in a funding round, dated September 6, 2019. Nkarta is based in South San Francisco, California, United States.

How much did Nkarta raise?
Nkarta raised $43.9 Million in a funding round on September 6, 2019.
What does Nkarta do?
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic natural killer (NK) cell therapies.
Where is Nkarta based and how big is it?
Nkarta is based in South San Francisco, California, United States. Fundz records about 147 employees.
Who are the decision-makers at Nkarta?
Fundz holds 1 contact at Nkarta, including the Associate Director. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Biotechnology around the same time

Companies in the same sectors as Nkarta that raised within 45 days of this round, from Fundz verified event records.

  • AliveCor, Inc. raised $5.8M on October 21, 2019.
  • TrueBinding raised $20M on October 21, 2019.
  • Eccrine Systems, Inc. raised $1.9M (Seed) on October 18, 2019.
  • Cell Source, Inc. raised $8.9M on October 18, 2019.
  • Icosavax, Inc. raised $30M on October 18, 2019.
  • Biogix, Inc. raised $2M (Seed) on October 17, 2019.

Who to call at Nkarta, and when

A new round usually means Nkarta is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Nkarta raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Nkarta, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Nkarta. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Nkarta

Location

South San Francisco, California, United States

About

Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic natural killer (NK) cell therapies. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of cell therapy candidates generated by efficient manufacturing processes, and engineered to enhance tumor targeting and improve persistence for sustained activity in the body.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Nkarta raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsMira T., Associate Director hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Nkarta's next move

See what Strategic adds

Nkarta raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.